Clearbridge Health Ltd. · SGX:1H3
Clearbridge Health — HY2018 Earnings Presentation
26 slides from Clearbridge Health's earnings presentation, Aug 14, 2018
Slide 1: Redefining Healthcare in Asia with Precision
REDEFINING HEALTHCARE IN ASIA WITH PRECISION EMPOWERING PATIENT CARE WITH CLARITY Corporate Presentation 2Q and HY2018
Slide 2: Important notice
Important notice Clearbridge Health Limited (the “Company”) was listed on the Catalist board of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) on 18 December 2017. This presentation has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, Unite
Slide 3: Content
Content 1. About Our Business 2. Operational Highlights 3. Prospects And Strategies 4. Investment Opportunities 5. Financial Highlights 6. Appendix 3
Slide 4: 1. About Our Business
1. About Our Business 4
Slide 5: Business Overview
• Precision medicine Building a - An approach for disease treatment and prevention that takes into Business precision medicine platform account individual variability in genes, environment and lifestyle • Approach Overview in Asia - Clinical data-driven initiatives - Collaborations with best-in-clas
Slide 6: 2. Operational Highlights
2. Operational Highlights 6
Slide 7: Completed acquisitions overview
Revenue by quarter PT Tirta Medika Jaya • 55% effective holding Completed 1,600 1,456 • Co-operate renal dialysis facilities acquisitions with over 20 hospitals throughout Indonesia overview 1,200 623 • Completed in end April 2018 • Valuation: S$10.0m (10x of forward- Proven track looking EBITDA of
Slide 8: Our Milestones
Our Milestones 2018 April 2018 January 2018 Clearbridge Health Clearbridge Health Partners A_STAR'S Marks Entry into GIS to offer The Philippines June 2018 April 2018 Prosigna Breast with Acquisition of Cancer Test in Medical Centre Clearbridge Completion of Singapore Acquisition of Partners With Sh
Slide 9: 3. Prospects and Strategies
3. Prospects and Strategies 9
Slide 10: Value creation strategies
Value creation strategies Multiple • Capitalising trading multiple differential between public Why EBITDA and and private market arbitrage M&A? • Reduce cost of capital by optimizing capital structure • EBITDA strengthens leverage capacity Leveraged • Continue pursuing multiple arbitrage opportuniti
Slide 11: Future plans
Future plans Growing scale and Deepening our scope while presence in optimising capital • Singapore, Indonesia structure and The Philippines Organic growth in • China, Myanmar, Malaysia and India 11
Slide 12: 4. Investment Opportunities
4. Investment Opportunities 12
Slide 13: Investment opportunities
EBITDA growth Primary healthcare services • Achieve positive • Build a compelling aesthetics Investment EBITDA business catering to all economic opportunities • Back by profitable segment of customers and high growth • Provide adjacent healthcare services businesses and leverage clinician channels 2
Slide 14: 5. Financial Highlights
5. Financial Highlights 14
Slide 15: Key financial highlights
Key financial highlights FPE 30 June (S$’000) 1QFY18 2QFY18 2QFY17 6MFY18 6MFY17 Revenue 377 1,456 3 1,833 5 Revenue and profit Loss before taxation (1,674) (12,159) (2,088) (13,833) (1,605) Loss attributable to owners of the company (1,489) (12,230) (38) (13,719) 16 FPE 30 June (S$’000) 2QFY18 6MFY
Slide 16: Key financial highlights
Key financial highlights Q1 FY2018 Q2 FY2018 6M FY2018 Adjusted EBITDAR Loss before taxation (1,674) (12,159) (13,833) Adjusted for following items: Fair value losses/(gains) on other investment, (795) 9,713 8,918 associates & derivative financial instruments Non-recurring operating expenses 420 691
Slide 17: Key financial highlights
Cash and Cash Total Assets 2Q2018 Key financial Equivalents S$15.1M 2Q2018 highlights S$19.27M S$65.8M Including undrawn facilities Strong cash position, FY2017 light asset base & FY2017 S$68.8M S$27.7M low debt Total Borrowings Total Borrowings (Current) (Non-Current) 2Q2018 2Q2018 S$10,000 S$1.6M
Slide 18: Thank You
Thank You E&OE Information provided on this presentation is accurate as at 14 August 2018
Slide 19: 6. Appendix
6. Appendix 19
Slide 20: Our Management Team
Our Management Team • Former CEO - Cordlife Group Limited (SGX-listed) Jeremy Yee • Former CFO - Cordlife Limited(1) Executive Director • M.Comm (University of Sydney), MBA (Chicago Booth), M.A (Columbia University) and CEO Simon Hoo Dr. Loo Han Woen Jonathan Liau Fexlicia Lee Chief Business CBMG (S
Slide 21: Clearbridge Medical Singapore
Clearbridge Medical Singapore Onze@Tanjong Pager 21
Slide 22: Clearbridge Medical Hong Kong
Clearbridge Medical Hong Kong Causeway Bay Collaborations / events 22
Slide 23: Clearbridge Medical Group Philippines
• Marzan Health Care renamed “Clearbridge Medical (Philippines), Inc.” to better Clearbridge reflect its association with our Group Medical Group • Its healthcare facility in Quezon City has been rebranded as Clearbridge Medical Philippines Centre (“CMC”) Rebranding of • 4-storey modern and well-equ
Slide 24: ClearSkin Advanced Dermatology & Laser Philippines
ClearSkin Advanced Dermatology & Laser Philippines Officially opened on 16 March 2018 Grand opening 24
Slide 25: Tirta Medika Jaya (TMJ) - Indonesia
Tirta Medika Jaya (TMJ) - Indonesia As at August 2018 • 20 hospitals under joint operation agreements Provision of renal (“JOA”) care services • 198 dialysis machines (out of 403 contracted) through operation of installed and in operation renal dialysis • Over 3,700 treatments per month facilities c
Slide 26: Future plans
Future plans Growing scale and Expand laboratory testing services scope while • Leverage early entrant advantage optimising capital • Strengthen market position structure • New complementary business areas 26